OliPass P/CF

Que fait OliPass ? OliPass Corp develops and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, and cancer immunotherapy medicine. The company also researches, develops, and sells functional cosmetics using artificial gene platform technology. Its primary customers are healthcare providers and pharmaceutical companies seeking innovative treatments and cosmetic solutions. OliPass Corp generates revenue through the sale of these medical products and functional cosmetics, focusing on biotechnology-driven healthcare and beauty markets. The company's product portfolio includes nonopioid analgesics for pain management, hyperlipidemia medicines for cholesterol control, ocular angiogenesis inhibitors for eye conditions, duchenne dystrophy treatments, and cancer immunotherapy medicines. Functional cosmetics developed via artificial gene platform technology target consumers interested in advanced skincare. OliPass Corp's revenue streams are derived from direct sales to healthcare institutions and pharmaceutical distributors, with a strong emphasis on biotech innovation in both medicine and cosmetics. OliPass Corp's business model centers on developing proprietary biological products through research and development. The firm sells its medicines and functional cosmetics to healthcare providers and pharmaceutical companies, leveraging its artificial gene platform technology for product differentiation. Revenue is generated through the commercialization of its medical and cosmetic product lines, which cater to specific health and beauty segments requiring advanced biotechnological solutions. OliPass est l'une des entreprises les plus populaires sur Eulerpool.